Sonjoy Laskar, MD
Advanced Heart Failure and Transplant Cardiology · Atlanta, GANPI 1821109604
Payments from drug & device makers
What this record shows
Abbott accounts for 75.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $1,410 and has fallen 97.6% since, to $34 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in GA, where the typical reported total is $8,076.
Across 15 payments — averaging $143.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Abiomed$380
- Medtronic$92
- Cvrx, Inc.$28
- Novo Nordisk$21
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$6
What the payments were for
- Travel & lodging$1,09051%
- Food & beverage$1,06849%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 9 | $1,631 |
| Abiomed | 2 | $380 |
| Medtronic | 1 | $92 |
| Cvrx, Inc. | 1 | $28 |
| Novo Nordisk | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,158 in reported general payments places this provider in the 20th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.
See all advanced heart failure and transplant cardiology providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 207 | $268,860 |
| FarxigaDapagliflozin Propanediol | 128 | $146,709 |
| EliquisApixaban | 127 | $125,900 |
| JardianceEmpagliflozin | 62 | $68,554 |
| Tacrolimus | 76 | $13,109 |
| XareltoRivaroxaban | 12 | $12,948 |
| Sirolimus | 24 | $7,124 |
| Eplerenone | 67 | $4,479 |
| Torsemide | 224 | $4,200 |
| Mycophenolate Mofetil | 36 | $4,157 |
| Potassium Chloride | 184 | $3,613 |
| Metoprolol Succinate | 247 | $2,631 |
| Spironolactone | 310 | $2,477 |
| Mexiletine Hcl | 23 | $2,364 |
| Carvedilol | 313 | $2,185 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Atlanta
- Robert ColeAtlanta$213K
- Rahul LounganiAtlanta$51K
- Arun KrishnamoorthyAtlanta$37K
- Benjamin DemossAtlanta$17K
- Mehrdad ToosiAtlanta$15K
- Brenda HottAtlanta$8K
- Divya GuptaAtlanta$8K
- Kunal BhattAtlanta$6K
- Mahmoud AbdouAtlanta$4K
- Chad MaoAtlanta$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.